Differences in Biologic Clinical Trials for Chronic Rhinosinusitis With Nasal Polyps-Are We Comparing Apples With...

Area of Science:

• Immunology
• Otolaryngology
• Clinical Trials

Background:

• Type 2 inflammation is a key driver in chronic rhinosinusitis with nasal polyps (CRSwNP).
• Several biologic therapies targeting Type 2 inflammation have emerged for CRSwNP treatment.
• Registrational randomized controlled trials (RCTs) are the primary source of efficacy data for these biologics.

Purpose of the Study:

• To identify and summarize key between-study differences in Phase III RCTs of biologics for CRSwNP.
• To highlight the challenges in comparing outcomes across these diverse trials.
• To inform future meta-analyses and treatment comparisons.

Main Methods:

• Review of published Phase III randomized controlled trials (RCTs) for biologics in CRSwNP.
• Identification and categorization of variations in patient populations, trial design, endpoints, and data handling.
• Analysis of how these differences impact outcome comparability.

Main Results:

• Significant heterogeneity exists across RCTs in terms of patient inclusion/exclusion criteria, disease severity, and prior treatment.
• Variations in primary and secondary endpoints, measurement tools, and assessment timing complicate direct comparisons.
• Differences in trial conduct, including geographical distribution and data analysis methodologies, further impact outcome interpretation.

Conclusions:

• Direct comparisons and meta-analyses of biologics for CRSwNP are complicated by substantial between-study heterogeneity.
• Failure to account for these differences can lead to inaccurate conclusions about relative efficacy.
• Standardization in trial design and reporting is needed to facilitate more robust comparisons of biologic therapies in CRSwNP.